Crossmark

ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era

Crossref DOI link: https://doi.org/10.1245/s10434-024-16265-x

Published Online: 2024-09-23

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Freeman, Jincong Q. https://orcid.org/0000-0002-1119-2146
Huo, Dezheng

Howard, Frederick M.
Funding

Funding for this research was provided by:

National Institute on Aging (T32AG000243)

Cancer Research Foundation

Agency for Healthcare Research and Quality (R03HS025806)

Lynn Sage Breast Cancer Foundation

Breast Cancer Research Foundation (BCRF-23-071)

U.S. Department of Defense (BC211095, BC211095P1)

Division of Cancer Prevention, National Cancer Institute (K08CA283261, P20CA233307)

Susan G. Komen (TREND21675016)
License Information

Text and Data Mining valid from 2024-09-23

Version of Record valid from 2024-09-23
More Information

Article History

Received: 9 September 2024

Accepted: 10 September 2024

First Online: 23 September 2024

Disclosure

: Frederick M. Howard has consulted with Novartis. The remaining authors have no conflicts of interest.

Document is current

Any future updates will be listed below